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Abstract Two human isoforms of membrane associated phos-
phatidic acid phosphatase have been described (PAP-2a and -2b),
and both enzymes have been shown to have broad substrate
specificity and wide tissue distribution [Kai et al., J. Biol. Chem.
272 (1997) 24572^24578]. With this report we describe a third
isoform, PAP-2c, that we found by searching the database of
expressed sequence tags (dbEST) with PAP-2a and PAP-2b
sequences. Key structural features described previously in PAP-
2a and -2b, including the glycosylation site, putative transmem-
brane domains, and the proposed catalytic site, are conserved in
the novel phosphatase. The kinetics of the three enzymes were
compared using as substrates phosphatidic acid, lysophosphatidic
acid, and N-oleoyl ethanolamine phosphatidic acid. Km values
for each of the substrates, respectively, were (in WM) PAP-2a:
98, 170, 116; PAP-2b: 100, 110, 56; and PAP-2c: 150, 340,
138. Expression of PAP-2c mRNA is more restricted than the
two previously described isoforms.
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1. Introduction
Phosphatidic acid phosphatases (PAPs) function in phos-
pholipid metabolism by catalyzing the conversion of phospha-
tidic acid (PA) to diacylglycerol. It has been shown recently
that PAPs also catalyze the hydrolysis of additional lipid
phosphoric acids, including the bioactive signaling molecules
lysophosphatidic acid (LPA), sphingosine 1-phosphate (S1P),
and ceramide 1-phosphate (Cer1P) [1,2]. Additionally, many
of the products of PAP-mediated hydrolysis (diacylglycerol,
sphingosine, and ceramide) are themselves important signaling
molecules [3^5]. These observations have attracted attention
to the role that PAPs may play in signal transduction. Due to
their apparent broad substrate speci¢city, PAPs are poised to
regulate several signaling pathways by simultaneously creating
and destroying bioactive lipids.
Initial biochemical characterization of PAP activity in rat
liver by Brindley and his associates demonstrated that the
enzyme activity could be separated into two components
[6,7]. Type 1 (PAP-1) was de¢ned as a cytosolic/endoplasmic
reticulum-localized activity that was both dependent on Mg2
and inactivated by the thio-reactive compound N-ethylmale-
imide (NEM). Conversely, a Mg2 dependent, NEM insensi-
tive membrane-associated activity was classi¢ed as type 2
(PAP-2). Further, PAP-1 was reported to translocate to mi-
crosomes on stimulation of triacylglyceride synthesis, while
PAP-2 was una¡ected by lipid metabolism status [6]. Only
the type 2 activity, however, is decreased in transformed ¢-
broblasts [8]. Therefore, it was hypothesized that PAP-1 is
involved in phospholipid metabolism while PAP-2 is involved
in signal transduction.
In 1992, Kanoh reported the partial puri¢cation of a 85 kDa
PAP-2 from porcine thymus. This activity was not in-
hibited by lysophosphatidic acid or diacetyl phosphatidate,
leading the authors to conclude that the enzyme was speci¢c
for PA [9]. The same group reported subsequently that the
phosphatase activity arose instead from a 35 kDa membrane-
bound, glycosylated protein that was a minor component of
their sample [10]. The sequence of an amino-terminal peptide
of the 35 kDa porcine PAP-2 was determined and used to
clone the mouse ortholog of PAP-2 based on high sequence
similarity to the partial cDNA clone hic53, a peroxide indu-
cible gene [11]. The peptide sequence of the mouse PAP-2
suggested six putative transmembrane domains and two gly-
cosylation sites [10]. In 1996, Waggoner et al. reported the
puri¢cation of PAP-2 from rat liver. In contrast to Kanoh’s
report, this group showed that the rat PAP-2 is not speci¢c
for PA, but rather can hydrolyse PA, LPA, S1P, and Cer1P
[2]. Subsequently, Dillon et al. showed that the enzyme could
hydrolyze diacylglyceride pyrophosphate (DGPP) also [12].
Kanoh’s group subsequently cloned two human isoforms of
PAP-2: PAP-2a and PAP-2b [1]. PAP-2a shares 83% sequence
identity with the original mouse PAP-2 while PAP-2b is 94%
identical to rat Dri42, whose gene product has been shown to
be localized to the ER and has been implicated in epithelial
cell di¡erentiation [13]. Both human clones are also related to
the Drosophila gene product Wunen, which has been impli-
cated in germ cell migration [14]. PAP-2a and -2b are 57%
identical over 253 amino acids and both were shown to be
glycosylated at a single site and are predicted by hydropathy
analysis to have six transmembrane regions [1]. The mem-
brane topology of Dri42 has been determined by the insertion
of Dri42 fusion proteins into microsomal membranes, and this
information has been used to predict the extracellular and
cytosolic domains of PAP-2a and PAP-2b [1,13].
Comparison of the PAP-2 sequences with those of vanadi-
um dependent peroxidases reveals striking sequence similarity
in regions of the vanadium binding sites and catalytic residues
of the peroxidases [15,16]. Wever’s group ¢rst proposed that
these two classes of enzymes share a common active site ar-
chitecture based on primary structure and similarity between
the geometries of vanadate and transition state phosphate
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[16]. Additionally, Neuwald has proposed a catalytic mecha-
nism of the phosphatases based on the analogous peroxidase
mechanism suggested by the crystal structure of the vanadi-
um-peroxidase complex. This putative phosphatase active
site is contained in three regions that are highly conserved
between the phosphatases and peroxidases, and all of these
regions are predicted to be in extracellular loops. This struc-
tural prediction indicates that PAP-2s may act as ectophos-
phatases.
If the PAP-2 enzymes function as ectophosphatases, they
may serve as regulators of the strength and duration of signals
from phosphorylated lipid mediators at cell surfaces. LPA
and S1P signal through G protein-coupled receptors that me-
diate a wide range of cellular events in response to binding of
the lipids [3^5]. Cell surface phosphatases could attenuate
these responses by a¡ecting the apparent potency of the li-
gands.
Obviously, substrate speci¢city is a critical parameter in
de¢ning the physiologic role of signal regulation by PAPs.
This study was initiated to de¢ne the substrate speci¢city of
the two human isoforms of PAP-2 by analyzing the kinetics of
their activity with PA, LPA and N-oleoyl ethanolamine phos-
phatidic acid (NOEPA) as substrates. After sub-cloning the
previously described PAP-2a and -2b cDNAs from EST
cDNAs, a third isoform was identi¢ed in the EST database
based on sequence similarity. We present here a description of
the novel enzyme, PAP-2c, and a comparison of the activities
of the three recombinant enzymes.
2. Materials and methods
2.1. cDNA cloning
Full length clones of human PAP-2a and -2b were found by search-
ing the EST database with the published amino acid sequences using
the TBLASTN algorithm [17]. Both of the underlying cDNAs were
obtained from the I.M.A.G.E. Consortium [18] (PAP-2a: clone ID
843414; PAP-2b: clone ID 23748). The novel phosphatase cDNA,
PAP-2c, was conceptualized from several EST sequences showing
high similarity scores with both PAP-2a and -2b. The 5PC3P order
of the overlapping sequences are as follows (by GenBank accession
number): AA429168, Z43618, N75714, AA316437, AA042850,
AA458529, R34980. The ¢rst clone in the series contained an initia-
tion codon near the initiation codons of the aligned PAP-2a and -2b
sequences. This cDNA (clone ID 769745) was acquired from
I.M.A.G.E. Consortium and sequenced. All three cDNAs were am-
pli¢ed by PCR using primers £anking the translational open reading
frames. The primers were designed to introduce restriction sites at
each end of the fragment, and these sites were used for subcloning
into the mammalian expression vector, pCR3.1 (Invitrogen).
2.2. Transfection and membrane preparation
Plasmid DNA was transfected into HEK 293 T cells using calcium
phosphate transfection protocol [19]. Brie£y, a DNA cocktail contain-
ing 25 Wg DNA and 0.25 M CaCl2 was added to HEPES bu¡ered
2 mM Na2HPO4. Subcon£uent monolayers of HEK 293 T cells were
poisoned with 25 mM chloroquine, and the DNA precipitate was then
applied to the cells. After 4 h, the monolayers were washed with PBS
and refed media (1:1 Dulbecco’s modi¢ed essential media: F12 + 10%
fetal bovine serum). The cells were harvested 48^72 h after addition of
the DNA. The cells were scraped in HME bu¡er (in mM: 20 HEPES,
5 MgCl2, 1 EDTA, pH 7.4) containing 10% sucrose on ice, and dis-
rupted using a Dounce homogenizer. After centrifugation at 800Ug,
the supernatant £uid was diluted with HME without sucrose and
centrifuged at 100 000Ug for 1 h. The resulting pellet was rehomo-
genized and centrifuged a second hour at 100 000Ug. This crude
membrane pellet was resuspended in HME with sucrose at 1^5 mg
protein/ml, aliquoted, and snap frozen by immersion in liquid nitro-
gen. The membranes were stored at 370‡C until use. Protein concen-
tration was determined spectroscopically by Bradford protein assay.
2.3. Radiolabeling lipids
32P-labeled phosphatidic acid, lysophosphatidic acid and N-oleoyl
ethanolamine phosphoric acid were prepared by reacting dioleoyl
glycerol (Sigma), mono-olein (NuChek Prep), or N-oleoyl ethanol-
amine (prepared as described by Lynch et al. [21]), respectively,
with [Q-32P]ATP in the presence of diacylglycerol kinase (Sigma) as
described by Walsh et al. [20]. The method used here di¡ers from the
published protocol in that the reaction size was increased 10-fold and
the reaction was allowed to proceed for 18 h. The labeled products
were puri¢ed by normal phase HPLC using a Varian Microsorb MV,
4.6 mmU250 mm, 5 Wm silica column. Lipids were eluted using the
following gradient pro¢le: isocratic solvent A (HCCl3/MeOH/H2O/
NH4OH: 77/21.65/0.85/0.5) from 0^5 min, linear transition from sol-
vent A to solvent B (HCCl3/MeOH/H2O/NH4OH: 59/34.5/6/0.5) from
5^15 min, and isocratic solvent B from 15 min onward. The collected
fractions were then washed with 0.1% HCl and MeOH and the or-
ganic phase was retained and dried.
2.4. Assay for PAP activity
Assays for phosphatase activity were carried out according to the
protocol described by Kanoh et al. [1], using a constant Triton
X-100:labeled lipid ratio of 50:1. The ¢nal speci¢c activity of the
lipids was adjusted to 10^50 Ci/mol. Brie£y, 10 Wg of membrane
protein was prewarmed to 37‡C in a reaction mixture containing
50 mM Tris-HCl (pH 7.5), 1 mM EDTA, and 1 mg/ml fatty acid-
free bovine serum albumin. Reactions were started by the addition of
the radiolabeled lipid-Triton X-100 mixture, kept at 37‡C for 5 min,
and stopped by the addition of 100 Wl 0.1 N HCl in methanol. 200 Wl
of CHCl3 and 200 Wl of 1 M MgCl2 were then added, and the reac-
tions were vortexed, centrifuged brie£y, and a fraction of the aqueous
layer was added to scintillation £uid for counting.
2.5. Northern blot
A multiple tissue Northern blot was purchased from Clontech Lab-
oratories and hybridized with radiolabeled cDNA according to the
manufacturer’s instructions. PAP-2c cDNA was radiolabeled by pri-
ming DNA synthesis with random hexamers in the presence of
K-[32P]dATP and K-[32P]dCTP (3000 Ci/mmol). The radiolabeled
DNA was separated from unincorporated nucleotides on a G-50
Sephadex spun column.
3. Results and discussion
3.1. Construction of PAP-2c
We searched the dbEST with the published sequences of
PAP-2a and PAP-2b [1] and identi¢ed and retrieved full
length cDNAs encoding both enzymes. We also found a set
of human EST sequences that were signi¢cantly similar, but
not identical, to both PAP-2a and PAP-2b. From these se-
quences, we conceptualized a putative third human isoform of
PAP-2. We obtained the cDNA of the ¢rst sequence in our
contig from the I.M.A.G.E. Consortium [18], and found it
encoded a full translational open reading frame (864
bpC288 aa) of the hypothetical protein, which we named
PAP-2c (Fig. 1A). PAP-2c is 58% identical to PAP-2a and
52% identical to PAP-2b. The three major regions of conser-
vation with the peroxidase proteins, including the amino acids
implicated in the phosphatase catalytic site, are conserved in
the novel isoform, as are the consensus site for N-linked gly-
cosylation and six putative transmembrane domains (Fig.
1B,C).
The activity of the three PAP isoenzymes was assayed using
membranes harvested from HEK 293 T cells that had been
transfected with the phosphatase DNAs. Membranes from
cells transfected with each of the cloned PAP-2s had several
fold higher activity than vector-DNA transfected cells (Fig. 2).
These data demonstrate that our copies of the two previously
reported PAP-2 cDNAs, as well as the cDNA for the putative
FEBS 20187 7-5-98
S.B. Hooks et al./FEBS Letters 427 (1998) 188^192 189
third isoform, encode functional phosphatases in our assay
system.
Con¢rming Kanoh’s observation of the puri¢ed porcine
PAP activity, we observed complete inhibition of all three
isoforms with 5 mM sphingosine. Mono-oleoyl glycerol also
inhibited PAP-2 activity, but to a lesser degree than sphingo-
sine. However, generic phosphatase inhibitors, including so-
dium pyrophosphate, para-nitrophenyl-phosphate, and L-D-
glycerol phosphate were unable to inhibit the activity of
PAP-2a, -2b or -2c at concentrations up to 5 mM (data not
shown).
3.2. Enzyme kinetics
Brindley’s group reported broad substrate speci¢city in the
PAP-2 they isolated from rat liver. Phosphatidic acid, lyso-
phosphatidic acid, sphingosine 1-phosphate, and ceramide
1-phosphate were all hydrolyzed by the puri¢ed enzyme
with Km values between 0.4 and 4.0 WM [2]. Likewise, Kanoh
et al. showed that recombinant human PAP-2a and PAP-2b
are not speci¢c for PA. When assayed at a single substrate
concentration (200 WM) PAP-2a was most active with PA and
LPA as substrates, displaying weak activity toward ceramide
1-phosphate and no activity toward sphingosine 1-phosphate.
PAP-2b showed the highest activity with PA and S1P as sub-
strates and had much lower activity when LPA or Cer1P were
substrates [1]. To characterize the substrate speci¢city of the
human isoforms of PAP, we developed kinetic pro¢les of the
previously tested recombinant enzymes, as well as the novel
PAP-2c, using 32P-labeled PA, LPA and NOEPA as sub-
strates.
NOEPA is an LPA mimetic with an ethanolamine rather
than a glycerol backbone, making it metabolically more stable
(i.e. it cannot be acylated) and more water soluble. NOEPA
has been shown previously by us to be indistinguishable from
LPA with respect to its activity in LPA functional assays [21].
We hypothesized that NOEPA is a naturally occurring lipid
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Fig. 2. The phosphatase activity of each membrane sample is shown
relative to the activity in vector transfected cells. The data shown
here are representative of several experiments, each performed in
triplicate. Similar data were also obtained using LPA and NOEPA
as substrates.
Fig. 1. A: DNA and conceptualized protein sequence of PAP-2c.
B: Alignment of the three human PAP-2 protein sequences. Con-
served residues are shaded, and the three major regions of similarity
to the peroxidase family are labeled A, B, and C. *: glycosylation
site. The alignment was constructed using the PILEUP algorith sup-
ported by the Wisconsin Package Version 9.1, Genetics Computer
Group (GCG), Madison, Wisconsin. C: Hydropathy plot of PAP-2c
protein sequence. A Kyte-Doolittle plot of the PAP-2c protein
sequence (window size: 9) suggests six transmembrane domains.
6
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signaling molecule. This hypothesis predicts that NOEPA, like
known lipid phosphoric acid mediators, must have a mecha-
nism for its destruction. PAP-2 is a likely candidate to per-
form this function based on its activity toward the structurally
similar compound LPA. If the ethanolamine backbone were
acylated with a polyunsaturated fatty acid (e.g. arachidonic
acid) the product of its hydrolysis by PAP-2 would be anand-
amide, the putative physiologic ligand for the G protein-
coupled cannabinoid receptors, CB1 and CB2 [22].
The curves describing the kinetic pro¢les of PAP-2a, -2b,
and -2c with PA, LPA, and NOEPA as substrates are shown
in Fig. 3 and the derived Vmax and Km values are given in
Table 1. The Vmax for each isoform is dependent on the trans-
fection e⁄ciency, so these values cannot be used for mean-
ingful comparison between the isoforms. They can be used,
however, to compare the relative ability of the di¡erent iso-
forms to hydrolyze each substrate. For both PAP-2a and
PAP-2b, the maximum activity of the enzymes are approxi-
mately 30% higher when PA is the substrate than when LPA
is substrate. In PAP-2c transfected cells, however, the maxi-
mum activity is higher when LPA is used as a substrate. The
maximum phosphatase activity when NOEPA is the substrate
is remarkably lower than LPA or PA in PAP-2c transfected
cells.
The a⁄nity of the enzymes for each substrate, indicated by
Km values, is independent of the enzyme concentration and
can therefore be compared between the di¡erent isoforms. All
three recombinant isoforms have similar a⁄nities for PA
(KmV100^150 WM). LPA, however, appears to be a more
selective substrate, with Kms of 170 WM, 110 WM, and
340 WM for PAP-2a, -2b, and -2c, respectively. Remarkably,
all three PAP-2 isoforms have a higher a⁄nity for NOEPA
than its structural analog, LPA.
The ability of the phosphatase to distinguish between LPA
and NOEPA while the receptor responsible for mediating
LPA signaling does not is potentially useful in further devel-
opment of lipid phosphoric acid medicinal chemistry. The
structural elements necessary for receptor binding may not
be necessary for recognition by the phosphatase and vice ver-
sa. It may be possible, then, to design a functional LPA mi-
metic that cannot be hydrolyzed by one or more of the PAP-2
isoforms, a useful tool in investigating the role of both LPA
and PAP-2.
3.3. PAP-2 mRNA expression
In Kanoh’s characterization of human PAP-2a and -2b,
Northern blot analysis showed expression of both mRNAs
in a wide range of tissues. Of the 16 tissues tested, PAP-2a
mRNA was detected in all except placenta, thymus, and leu-
kocytes, with particularly high expression in prostate, while
PAP-2b mRNA was expressed ubiquitously [1]. The high ex-
pression of PAP-2a in prostate is intriguing in view of the
recent report that expression of PAP-2a is androgen depend-
ent in the prostatic adenocarcinoma cell line, LNCaP [23].
In contrast, when the cDNA of PAP-2c was hybridized to a
Northern blot panel of human poly(A) RNA, it revealed a
more restrictive expression pattern (Fig. 4). RNA of approx-
imately 1.4 kb was detected in extracts of brain and pancreas,
and a somewhat smaller (V1.3 kb) and more abundant
mRNA was found in placenta. The EST cDNAs for human
PAP-2c were derived from the following tissue libraries : preg-
nant uterus, fetal liver spleen, infant brain, ovary tumor, pla-
centa and pancreas. The narrower expression pattern of PAP-
2c may imply a more specialized role than the other two iso-
forms.
Finally, the kinetic data reported here, while useful in com-
paring the relative activity of the enzymes and their a⁄nities
for di¡erent substrates, has limited physiological relevance
due to the presentation of the lipids as Triton X-100 micelles.
Therefore, we are working currently to de¢ne PAP-2 activity
with the substrates loaded onto albumin, as the bioactive
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Table 1
Km and Vmax values for the three PAP isoforms
Fig. 3. The kinetic behavior of each of the three PAP-2 isoforms
were determined with PA, LPA, and NOEPA as substrates. Each
concentration was assayed in triplicate. The results were analyzed
by Prism Graphpad, using a non-linear regression.
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lipids may be presented to the surfaces of cells in vivo. Our
characterization is also being expanded to include sphingosine
1-phosphate and other lipid signaling molecules.
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Fig. 4. Northern blot hybridization with PAP-2c DNA was per-
formed with a CLONTECH multiple human tissue blot. Lanes con-
tain 2 Wg poly(A) RNA from: A, heart; B, brain; C, placenta;
D, lung; E, liver; F, skeletal muscle; G, kidney; H, pancreas.
L-Actin cDNA was used as a control hybridization probe.
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